InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

31 October, 2019

InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

Please click here to read InteRNA Poster showing the data

NEWS

18 May, 2020

Recently a short movie about InteRNA and it’s lead compound for the treatment of cancer was broadcasted in the RTL4/RTLZ program “Zo kan het ook”. Watch the video with the latest news here

6 May, 2020

InteRNA Technologies Receives Regulatory Approval for Initiation of Phase I Clinical Trial of INT-1B3 in Patients with Advanced Solid Tumors

25 March, 2020

InteRNA steunt de campagne Innovaties in Oncologie van @Mediaplanet. Leer meer over verschillende innovaties in oncologie zoals immuuntherapieën van thought leaders, zoals Ton Schumacher online of in de New Scientist (24 maart 2020)

31 October, 2019

InteRNA presents data on potential of lead oncology development candidate INT-1B3 in immuno-oncology at the SelectBIO Immuno-Oncology Europe 2019 meeting

31 October, 2019

InteRNA presents data on drug formulation and mode of action of lead oncology development candidate INT-1B3 at the 15th annual OTS meeting

1-5 6-10 11-15 16-20 21-25 26-30 31-35 36-38